Atara Biotherapeutics, Inc. - Common Stock (ATRA) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2014 to Q3 2025

Type / Class
Equity / Common Stock
Symbol
ATRA on Nasdaq
Shares outstanding
8,165,808
Price per share
$14.33
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
15
Total reported value
$215
% of total 13F portfolios
0%
Share change
+15
Value change
+$215
Number of holders
1
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Atara Biotherapeutics, Inc. - Common Stock (ATRA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Panacea Innovation Ltd 20% -0.05% -$1,154,619 1,632,345 -4.7% Panacea Innovation Limited 12 Jan 2026
Adiumentum Capital Fund I LP 20% 1,370,081 Adiumentum Capital Fund I LP 14 May 2025

As of 30 Sep 2025, 1 institutional investors reported holding 15 shares of Atara Biotherapeutics, Inc. - Common Stock (ATRA). This represents 0% of the company’s total 8,165,808 outstanding shares.

Institutional Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 15 $215 +$215 $14.33 1
2025 Q1 0 $0 -$839 $14.33 0
2024 Q4 63 $839 $13.32 2
2024 Q3 35 $285 -$1,511,256 $8.14 1
2024 Q2 182,077 $1,511,600 -$88,647,049 $8.50 5
2024 Q1 83,249,933 $57,775,105 +$13,539,594 $0.69 80
2023 Q4 64,725,654 $33,190,425 -$41,739,808 $0.51 89
2023 Q3 88,187,935 $130,517,483 -$3,294,604 $1.48 108
2023 Q2 90,354,566 $145,469,168 -$23,260,244 $1.61 115
2023 Q1 102,693,551 $297,884,697 +$14,378,615 $2.90 124
2022 Q4 97,400,862 $319,467,221 -$2,173,205 $3.28 138
2022 Q3 97,668,961 $369,193,024 -$18,917,474 $3.78 149
2022 Q2 99,815,040 $777,439,383 +$14,024,584 $7.79 132
2022 Q1 97,877,569 $909,405,142 +$12,542,757 $9.29 139
2021 Q4 93,317,058 $1,470,768,390 +$63,749,519 $15.76 137
2021 Q3 87,844,034 $1,572,372,278 +$69,603,688 $17.90 138
2021 Q2 85,946,359 $1,336,531,861 -$10,054,279 $15.55 144
2021 Q1 85,650,758 $1,229,931,921 -$3,128,334 $14.36 148
2020 Q4 86,646,814 $1,700,929,395 +$61,203,871 $19.63 144
2020 Q3 83,809,041 $1,086,847,081 +$59,533,643 $12.96 138
2020 Q2 77,585,671 $1,130,387,589 +$244,721,751 $14.57 121
2020 Q1 62,604,589 $531,867,879 +$2,830,287 $8.51 106
2019 Q4 61,123,347 $1,006,681,660 +$38,331,911 $16.47 112
2019 Q3 59,009,784 $833,183,512 +$118,059,357 $14.12 111
2019 Q2 50,296,513 $1,011,718,530 +$11,334,650 $20.11 114
2019 Q1 48,808,849 $1,940,163,733 +$25,166,384 $39.75 118
2018 Q4 48,253,940 $1,676,297,014 +$62,510,625 $34.74 119
2018 Q3 46,348,347 $1,916,490,444 -$3,168,582 $41.35 114
2018 Q2 46,455,501 $1,707,224,921 +$103,228,229 $36.75 122
2018 Q1 43,618,390 $1,698,364,623 +$561,989,584 $39.00 113
2017 Q4 29,837,777 $541,854,369 +$35,717,603 $18.10 82
2017 Q3 26,588,544 $441,130,415 +$15,294,795 $16.55 80
2017 Q2 25,741,068 $360,377,428 +$19,806,324 $14.00 80
2017 Q1 23,968,978 $492,552,713 +$57,013,769 $20.55 82
2016 Q4 23,232,402 $329,896,488 +$8,113,819 $14.20 83
2016 Q3 22,400,142 $479,016,785 +$15,346,848 $21.39 72
2016 Q2 21,590,915 $486,014,073 +$46,726,583 $22.51 70
2016 Q1 19,799,648 $376,755,000 +$7,120,067 $19.03 69
2015 Q4 19,264,140 $508,636,288 -$21,986,693 $26.41 83
2015 Q3 19,482,171 $612,517,952 +$196,917,062 $31.44 87
2015 Q2 13,191,481 $695,961,994 +$107,658,520 $52.76 74
2015 Q1 11,227,473 $461,513,969 +$185,585,180 $41.57 52
2014 Q4 6,725,410 $172,103,401 +$161,930,701 $26.75 39